“…The ANX2 heterotetramer acts as a receptor for plasminogen, tissue-type plasminogen activator and tenascin C, and is implicated in extracellular matrix degradation (Gerke et al, 2005). The ANX2 is not observed in normal hepatocytes, the pancreatic exocrine system and the mammary gland (Frohlich et al, 1990;Dreier et al, 1998;MasseyHarroche et al, 1998); in tumours that arise from these tissues, such as hepatocellular carcinoma, pancreatic cancer and breast cancer, respectively, ANX2 expression is observed as membrane and/or cytoplasmic staining (Frohlich et al, 1990;Diaz et al, 2004;Sharma et al, 2006). Esposito et al (Esposito et al, 2006) reported that ANX2 expression changed from cytoplasmic to cell surface expression with progression of pancreatic cancer.…”